Shan Naing L, Shin Yoosub, Yang Ge, Furmanski Philip, Suh Nanjoo
Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
Yonsei University, College of Medicine, Seoul, Republic of Korea.
Mol Carcinog. 2021 Feb;60(2):73-100. doi: 10.1002/mc.23277. Epub 2021 Jan 11.
The evolving concept that cancer stem cells (CSCs) are the driving element in cancer development, evolution and heterogeneity, has overridden the previous model of a tumor consisting of cells all with similar sequentially acquired mutations and a similar potential for renewal, invasion and metastasis. This paradigm shift has focused attention on therapeutically targeting CSCs directly as a means of eradicating the disease. In breast cancers, CSCs can be identified by cell surface markers and are characterized by their ability to self-renew and differentiate, resist chemotherapy and radiation, and initiate new tumors upon serial transplantation in xenografted mice. These functional properties of CSCs are regulated by both intracellular and extracellular factors including pluripotency-related transcription factors, intracellular signaling pathways and external stimuli. Several classes of natural products and synthesized compounds have been studied to target these regulatory elements and force CSCs to lose stemness and/or terminally differentiate and thereby achieve a therapeutic effect. However, realization of an effective treatment for breast cancers, focused on the biological effects of these agents on breast CSCs, their functions and signaling, has not yet been achieved. In this review, we delineate the intrinsic and extrinsic factors identified to date that control or promote stemness in breast CSCs and provide a comprehensive compilation of potential agents that have been studied to target breast CSCs, transcription factors and stemness-related signaling. Our aim is to stimulate further study of these agents that could become the basis for their use as stand-alone treatments or components of combination therapies effective against breast cancers.
癌症干细胞(CSCs)是癌症发生、发展和异质性的驱动因素,这一不断演变的概念已经取代了先前认为肿瘤由所有细胞具有相似的顺序获得性突变以及相似的更新、侵袭和转移潜能的模型。这种范式转变将注意力集中在直接靶向癌症干细胞作为根除疾病的一种治疗手段上。在乳腺癌中,癌症干细胞可通过细胞表面标志物来识别,其特征在于自我更新和分化的能力、抵抗化疗和放疗的能力以及在异种移植小鼠中连续移植后引发新肿瘤的能力。癌症干细胞的这些功能特性受到细胞内和细胞外因素的调节,包括多能性相关转录因子、细胞内信号通路和外部刺激。已经研究了几类天然产物和合成化合物来靶向这些调节元件,迫使癌症干细胞丧失干性和/或终末分化,从而实现治疗效果。然而,专注于这些药物对乳腺癌症干细胞的生物学效应、其功能和信号传导的有效乳腺癌治疗方法尚未实现。在本综述中,我们描述了迄今为止已确定的控制或促进乳腺癌症干细胞干性的内在和外在因素,并全面汇编了已研究的靶向乳腺癌症干细胞、转录因子和干性相关信号传导的潜在药物。我们的目的是激发对这些药物的进一步研究,这些药物可能成为其作为独立治疗方法或有效对抗乳腺癌的联合治疗组成部分的基础。